Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder

Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder

This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.

This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.

Qualified schizophrenia patients will be enrolled to an 12-week treatment phase of Aripiprazole by physician's assessment.

Qualified bipolar disorder patients will be enrolled to an 8-week treatment phase of Aripiprazole by physician's assessment.

This study will be continued for 6 years. The final report of Aripiprazole PMS will be submitted to KFDA on December 28, 2009.

Inclusion Criteria:

• Patient with a schizophrenia or schizoaffective disorder or bipolar disorder according to DSM-IV criteria
• Age: more than 18 years of age

Exclusion Criteria:

• Unqualified patients judged by study investigator(s)